Prebiotics for inflammatory bowel disease: Animal studies (Part 1)

Published studies to date on the use of prebiotics in IBD models have established proof of principle in animals (Table 1). Models used include the interleukin-10 knockout mouse that tends to reproduce a colitis resembling CD. Although the mice are normal at birth, by four weeks they develop a mild colitis which reaches a maximum severity by eight weeks. Madsen et al have published at least two relevant studies with this model. In the first report, orally administered lactulose or Lactobacillus reuteri by rectal enema were able to attenuate colitis. In the second study, breast milk from normal wild mice fed to interleukin-10-deficient mice also failed to develop colitis. While mouse-derived breast milk may be different from that of humans, the latter contains many components including lactoferrin (which can inhibit bacterial pathogen growth). However, fructooligosaccharides (FOS) in human milk are considered to be an important prebiotic element with bifidogenic properties. It is likely that similar processes could apply to mouse-derived breast milk. The use of dextran sulfate sodium produces a disease resembling UC after ingestion. At least six studies using this model of UC have shown response to a variety of prebiotics (inulin , lactulose or GBF ), with clinical improvement, increased measurable SCFAs or markers of oxidative damage (like myeloperoxidase). After reading all the valuable information above, you can choose the right medications for your condition and buy them at the – the best online pharmacy offering generic medications over the internet.

TABLE 1 Animal studies of inflammatory bowel disease using prebiotics

Author Model Prebiotic Outcome
Madsen et al Interleukin-10 knockout mice Oral lactulose Prevents spontaneous colitis
Madsen et al Interleukin-10 knockout mice Breast milk Prevents colitis
Videla et al DSS colitis rats Oral 1% inulin 400 mg/day Prevents colitis
Rumi et al DSS colitis rats Lactulose 300 mg/kg to 1000 mg/kg D  short chain fatty acids D  inflammation
Araki et al DSS colitis rats GBF Prevents colitis I  acetic acid,   I  butyric acid   I bifidobacteria and eubacteria   D aerobic bacteria and Bacteroides
Fukuda et al DSS colitis rats GBF D  myeloperoxidase D  pH
Kanauchi et al DSS colitis rats GBFGBF + 5-aminosalicylic acid D  clinical inflammation   I cecal short chain fatty acids (combination better)
Kanauchi et al DSS colitis mice GBF Prevents clinical histological colitis
Holma et al Trinitrobenzene sulfonic acid rats 48 mg/kg transgalactooligosaccharides I  bifidobacteria/no prevention of colitis
Cherbut et al Trinitrobenzene sulfonic acid rats Intragastric fructooligosaccharides Improved histology of colitis

DSS Dextran sulfate sodium; GBF Germinated barley foodstuff; D Decrease; I Increase


This entry was posted in Inflammatory bowel disease and tagged , .